Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

[M24-555]Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071250057

Enrollment

Registered

2025-08-04

Start date

2025-08-12

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Multiple doses of etentamig in combination with iberdomide will be explored. Phase 1: ABBV-383 Dose Escalation In phase 1 participants will receive escalating intravenous (IV) etentamig in combinati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance of 0 to 1. Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol. All participants must have measurable diseases per central laboratory as outlined in protocol.

Exclusion criteria

Exclusion criteria: Has received prior etentamig treatment. Prior exposure to BCMA-targeted therapy as noted in the protocol. Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).

Design outcomes

Primary

Measure	Time frame
Dose-Limiting Toxicities (DLT) Adverse Events (AE)s	—

Secondary

Measure	Time frame
Partial Response (PR) Response Rate (RR) Very Good Partial Response (VGPR) RR Complete Response (CR) RR Stringent Complete Response (sCR) RR Overall Response Rate (ORR) Progression-Free Survival (PFS) Duration of Response (DOR) Time-to-Progression (TTP) Minimal Residual Disease (MRD) negativity	—

Countries

Australia, Japan

Contacts

Public ContactPatients and HCP Contact

AbbVie GK

AbbVie_JPN_info_clingov@abbvie.com+81-120-587-874

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026